Clinical trials: SCCHN
Squamous Cell Carcinoma of the Head and Neck
Definitive Concurrent Hypofractionated Rth With Weekly Cisplatin in Locally Advanced SCCHN
The primary endpoint will be acute toxicity. Secondary endpoints included: late toxicity and quality of life; loco-regional control, disease free survival and overall survival.
- Trial name
- NCT03880396
- Testing
- hypofractionated Rth with platinol
- Where
- Egypt
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Assiut University
Circulating Tumor Cell, Squamous Cell Carcinoma of the Head and Neck
CTC Detection Rate in SCCHN With a in Vivo Device
Detection rate and isolation yield of CTC is low in squamous cell carcinoma of head and neck (SCCHN) with in vitro approaches rely on limited sample volumes.
- Trial name
- NCT03071900
- Testing
- circulating tumor cell analysis
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Nanjing Tongren Hospital
Advanced Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Study of Docetaxel in Combination With Cisplatin and 5-Fluorouracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to determine the appropriate dose, that dose which is found to give maximum effect with limited toxicity, of cisplatin in combination with docetaxel and 5-fluorouracil and then to further define the…
- Conditions
- Advanced Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, SSCHN
- Trial name
- NCT00139269
- Testing
- Docetaxel, Cisplatin, 5-Fluorouracil
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Dana-Farber Cancer Institute